146 related articles for article (PubMed ID: 33008846)
1. Factors Associated With Delayed Contraceptive Implant Removal in Ethiopia.
Costenbader E; Cartwright AF; McDowell M; Assefa B; Tejeji MY; Tenaw E
Glob Health Sci Pract; 2020 Sep; 8(3):455-465. PubMed ID: 33008846
[TBL] [Abstract][Full Text] [Related]
2. Improving Contraceptive Access, Use, and Method Mix by Task Sharing Implanon Insertion to Frontline Health Workers: The Experience of the Integrated Family Health Program in Ethiopia.
Tilahun Y; Lew C; Belayihun B; Lulu Hagos K; Asnake M
Glob Health Sci Pract; 2017 Dec; 5(4):592-602. PubMed ID: 29229650
[TBL] [Abstract][Full Text] [Related]
3. Addressing unmet need for long-acting family planning in Ethiopia: uptake of single-rod progestogen contraceptive implants (Implanon) and characteristics of users.
Asnake M; Henry EG; Tilahun Y; Oliveras E
Int J Gynaecol Obstet; 2013 Nov; 123 Suppl 1():e29-32. PubMed ID: 24035007
[TBL] [Abstract][Full Text] [Related]
4. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
[TBL] [Abstract][Full Text] [Related]
5. The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding.
Ireland LD; Goyal V; Raker CA; Murray A; Allen RH
Contraception; 2014 Sep; 90(3):253-8. PubMed ID: 24973904
[TBL] [Abstract][Full Text] [Related]
6. Influence of age on tolerability, safety and effectiveness of subdermal contraceptive implants.
López Del Cerro E; Serrano Diana C; Castillo Cañadas AM; González Mirasol E; García Santos F; Gómez García MT; González de Merlo G
J Obstet Gynaecol; 2018 Oct; 38(7):979-984. PubMed ID: 29553853
[TBL] [Abstract][Full Text] [Related]
7. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
[TBL] [Abstract][Full Text] [Related]
8. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
Saloranta TH; Gyllenberg FK; But A; Gissler M; Laine MK; Heikinheimo O
Am J Obstet Gynecol; 2020 Dec; 223(6):886.e1-886.e17. PubMed ID: 32562657
[TBL] [Abstract][Full Text] [Related]
9. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
[TBL] [Abstract][Full Text] [Related]
10. Six- and twelve-month documented removal rates among women electing postpartum inpatient compared to delayed or interval contraceptive implant insertions after Medicaid payment reform.
Crockett AH; Pickell LB; Heberlein EC; Billings DL; Mills B
Contraception; 2017 Jan; 95(1):71-76. PubMed ID: 27400823
[TBL] [Abstract][Full Text] [Related]
11. Familiarity and acceptability of long-acting reversible contraception and contraceptive choice.
Paul R; Huysman BC; Maddipati R; Madden T
Am J Obstet Gynecol; 2020 Apr; 222(4S):S884.e1-S884.e9. PubMed ID: 31838124
[TBL] [Abstract][Full Text] [Related]
12. Postpartum contraception: initiation and effectiveness in a large universal healthcare system.
Brunson MR; Klein DA; Olsen CH; Weir LF; Roberts TA
Am J Obstet Gynecol; 2017 Jul; 217(1):55.e1-55.e9. PubMed ID: 28257962
[TBL] [Abstract][Full Text] [Related]
13. Use of etonogestrel implant beyond approved duration: prolonged contraceptive effectiveness.
Ribeiro BC; Nogueira-Silva C; Afonso H; Silva PO; Reis ID
Eur J Contracept Reprod Health Care; 2018 Aug; 23(4):309-310. PubMed ID: 30203680
[TBL] [Abstract][Full Text] [Related]
14. Reasons for requesting removal of the hormonal implant, Implanon NXT, at an urban reproductive health clinic in KwaZulu-Natal, South Africa.
Beesham I; Smit J; Beksinska M; Panday M; Makatini V; Evans S
S Afr Med J; 2019 Sep; 109(10):750-755. PubMed ID: 31635572
[TBL] [Abstract][Full Text] [Related]
15. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
McNicholas C; Swor E; Wan L; Peipert JF
Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
[TBL] [Abstract][Full Text] [Related]
16. What Goes In Must Come Out: A Mixed-Method Study of Access to Contraceptive Implant Removal Services in Ghana.
Callahan R; Lebetkin E; Brennan C; Kuffour E; Boateng A; Tagoe S; Coolen A; Chen M; Aboagye P; Brunie A
Glob Health Sci Pract; 2020 Jun; 8(2):220-238. PubMed ID: 32606092
[TBL] [Abstract][Full Text] [Related]
17. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review.
Sanders JN; Turok DK; Gawron LM; Law A; Wen L; Lynen R
Am J Obstet Gynecol; 2017 Jun; 216(6):590.e1-590.e8. PubMed ID: 28188772
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.
Wenzl R; van Beek A; Schnabel P; Huber J
Contraception; 1998 Nov; 58(5):283-8. PubMed ID: 9883383
[TBL] [Abstract][Full Text] [Related]
19. Training contraceptive providers to offer intrauterine devices and implants in contraceptive care: a cluster randomized trial.
Thompson KMJ; Rocca CH; Stern L; Morfesis J; Goodman S; Steinauer J; Harper CC
Am J Obstet Gynecol; 2018 Jun; 218(6):597.e1-597.e7. PubMed ID: 29577915
[TBL] [Abstract][Full Text] [Related]
20. Early removal of etonogestrel subcutaneous contraceptive implant at a community health centre in Pretoria.
Moeti DMP; Govender I; Bongongo T
S Afr Fam Pract (2004); 2022 Jul; 64(1):e1-e6. PubMed ID: 35924618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
